Tuesday 1st August 2017 is World Lung Cancer Day

Lung cancer continues to be one of the most common cancers worldwide, claiming more lives yearly than breast, colon, and prostate cancers combined. It is estimated that lung cancer accounts for nearly one in five cancer deaths globally. In 2012, there were 1.8 million newly diagnosed cases of lung cancer alone. The American College of Chest Physicians (CHEST), alongside members of the Forum of International Respiratory Societies (FIRS) commemorates, celebrates and supports those impacted by lung cancer. FIRS joins the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its global impact, creating an educational movement of understanding lung cancer risks as well as early treatment around the world.

The History of World Lung Cancer Day

Lung cancer was a rare disease in early 20th century but its incidence has gradually increased with increased smoking and it has become the most common type of cancer in the world. The lung cancers accounts for 12.8% of cancer cases and 17.8% of mortalities of cancer worldwide. Lung cancer is a preventable disease. The factors that play a role in cancer development include tobacco products, industrial products (uranium, radiation, asbestos) air pollution, and nutritional deficiencies. Recent studies have demonstrated that the critical factor increasing the risk of lung cancer is the long-term respiration of carcinogenic materials.

Epidemiologic case-control studies by 1950s proved that smoking was strongly correlated with lung cancer. The first findings that smoking was a cause of lung cancer were published in 1962. Smoking is responsible for developing lung cancer by 94%. The risk of lung cancer is 24-36 times higher in smokers than in non-smokers. The risk is 3.5% in passive smoking. Age to start smoking, period of smoking, number of cigarettes smoked, and type of tobacco and cigarette have influence on the risk of developing lung cancer.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The